

**John C. Puente, M.D.**  
CCT Research  
1910 S Stapley Drive, Suite 120  
Mesa, AZ 85204

**CONTACT INFORMATION:**

Site Selection and Information:  
Bobbie Theodore, VP Sponsor Relations/BD  
Apex Innovative Sciences, Alliance Division  
Tel. 916-803-7149 (cell)  
Email: [bobbietheodore@apexsci.com](mailto:bobbietheodore@apexsci.com)

**AFFILIATIONS:**

Bryan LGH Medical Centers  
East Campus  
1600 S. 48th St.  
Lincoln, NE 68506  
West Campus  
2300 S. 16th St.  
Lincoln, NE 68502

St. Elizabeth's Regional Medical Center  
555 S 70<sup>th</sup> Street  
Lincoln, NE

Beatrice Community Hospital  
4800 Hospital Parkway  
Beatrice, NE 68310-6906

St. Mary's Hospital  
1301 Grundman Blvd.  
Nebraska City, NE

The Heritage at Sterling Ridge/CCT Research  
1111 Sterling Ridge Drive  
Omaha, NE 68144

West Omaha Family Physicians, P.C./CCT Research  
17030 Lakeside Hills Plaza, Suite 130  
Omaha, NE 68130

Skyline Medical Center, PC/ CCT Research  
1908 N 203rd Street, Suite #2  
Elkhorn, NE 68022

**AFFILIATIONS (*continued*):**

Methodist Physicians Clinic/CCT Research  
350 W 23rd  
Fremont, NE 68025

**EDUCATION:**

1996-00      M.D.  
                  University of Nebraska Medical Center, Omaha, NE

1989-92      B.S.  
                  Business Administration in Finance, Creighton University, Omaha, NE

**LICENSURE:**

Nebraska Medical License #22773

**INTERNSHIPS AND RESIDENCIES:**

2000-04      Chief Resident Neurology  
                  University of Nebraska Medical Center, Omaha, NE

**CERTIFICATION:**

Board Certified Neurology, State of Nebraska  
ACLS Certification  
NIH Stroke Scale Certification

**PROFESSIONAL EXPERIENCE:**

*Principal Investigator*, 2018 – present  
CCT Research, Scottsdale, AZ

*Neurologist*, 2016- Present  
Neurology Consultants of Nebraska, P.C., Omaha, NE

*Company President & Neurologist*, 2013-16  
Multiple Sclerosis Center of Nebraska, P.C., Lincoln, NE

*Neurologist*, 2011-13  
Neurological and Spinal Surgery, L.L.C., Lincoln, NE

*Neurologist*, 2004-11  
Neurology Associates, P.C., Lincoln, NE

**INVESTIGATOR EXPERIENCE:**

ALS • Alzheimer's Disease • COVID-19 Treatment • Multiple Sclerosis  
Neuropathic Pain • Parkinson's Disease

**INVESTIGATOR EXPERIENCE:**

***Alzheimer's Disease***

A Phase II, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of XXX in Subjects with Mild-to-Moderate Alzheimer's Disease

A Phase III, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of XXX in treatment of mild to moderate Alzheimer's disease

A Phase III, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

A 12-Month, Open-Label Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase IIa, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of XXX in Mild-to-moderate Alzheimer's Disease Patients

A Phase III Safety and Efficacy Study of XXX in Subjects With Evidence of Early Alzheimer's Disease

***ALS***

A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of the Safety and Efficacy of XXX in Subjects with Amyotrophic Lateral Sclerosis

***Multiple Sclerosis***

A Phase III, Randomized, Double-blind Efficacy and Safety Study Comparing Oral XXX to Oral XXX in Participants With Relapsing Forms of Multiple Sclerosis (RMS-1)

A Phase III XXX vs XXX Trial, a Registrational Study Evaluating Treatment in Subjects with Relapsing Multiple Sclerosis

**INVESTIGATOR EXPERIENCE (*continued*):**

A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient Reported Outcomes of Oral XXX (XXX) Delayed-Release Capsules in Patients with Relapsing Forms of Multiple Sclerosis After Response to XXX

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of XXX Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

A Multicenter, Observational, Open-Label, Single-Arm Study of XXX in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX: Stratify-2

***Parkinson's Disease***

Multicenter, Double-blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of XXX on Motor Symptoms in Patients with Advanced Parkinson's Disease with Motor Fluctuations and Gastroparesis

***Other Indications***

A Phase II, Multicenter Adaptive Randomized Double-Blind Placebo Controlled Platform Trial of the Efficacy and Safety of XXX in COVID-19 Adults not Requiring Hospitalization at Time of Diagnosis

An Evaluation of the ctDNA XXX Test in an Average Patient Colorectal Cancer Screening Episode

A Phase II, Randomized, Double-blind, Placebo and Active Comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX in the Treatment of Diabetic Peripheral Neuropathic Pain

Named Protocol XXX Patient Program with XXX